-

07:43:23 PM

ASLN Stock News

ASLN - ASLAN Pharmaceuticals Ltd

11/22/21 7:00 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will be

RHEA-AI

neutral

11/10/21 7:00 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate

RHEA-AI

neutral

10/26/21 7:00 AM

Nasdaq : ASLN

earnings

ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose (MAD) trial in patients with moderate-to-severe atopic dermatitis (AD) On track to initiate Phase 2b 300-patient clinical trial for ASLAN004 in 4Q 2021 Company maintains strong operating position

RHEA-AI

neutral

10/22/21 7:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced a collaboration with renowned inflammatory

RHEA-AI

positive

10/18/21 7:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004

RHEA-AI

neutral

10/14/21 7:00 AM

Nasdaq : ASLN

management

ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointments of Dr Melinda Jennifer

RHEA-AI

positive

09/27/21 6:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.025 1 ) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant

RHEA-AI

neutral

09/22/21 7:00 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a

RHEA-AI

neutral

09/21/21 7:00 AM

Nasdaq : ASLN

management

ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence

RHEA-AI

very positive

09/09/21 7:00 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a

RHEA-AI

neutral

ASLN Data:

IndustryPharmaceutical Preparation Manufacturing
Websiteaslanpharma.com
CeoCarl Firth
Security nameASLAN Pharmaceuticals Ltd - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
State12 03 Ue Square
City83 Clemenceau Avenue
Zip239920
CountrySingapore
Phone6562224235

ASLN Description:

ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.